GlaxoSmithKline Accumulated Other Comprehensive Income from 2010 to 2024

GSK Stock   1,340  3.50  0.26%   
GlaxoSmithKline PLC's Accumulated Other Comprehensive Income is increasing over the years with slightly volatile fluctuation. Overall, Accumulated Other Comprehensive Income is expected to go to about 1.7 B this year. Accumulated Other Comprehensive Income is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. View All Fundamentals
 
Accumulated Other Comprehensive Income  
First Reported
1995-06-30
Previous Quarter
969 M
Current Value
1000 M
Quarterly Volatility
3.9 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 502.2 M or Total Revenue of 19.9 B, as well as many indicators such as . GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
This module can also supplement various GlaxoSmithKline PLC Technical models . Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in GlaxoSmithKline Stock

GlaxoSmithKline PLC financial ratios help investors to determine whether GlaxoSmithKline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GlaxoSmithKline with respect to the benefits of owning GlaxoSmithKline PLC security.